Publication
Abstract
Realization of part of a clinical trial called Prospective, randomized, double-blind Phase 3 clinical trial comparing product rhBSSL a placebo added to infant baby formula or pasteurized breast milk during a 4-week treatment of preterm infants born before 32 weeks gestational age